This category needs an editor. We encourage you to help if you are qualified.
Volunteer, or read more about what this involves.
Related categories

657 found
Order:
1 — 50 / 657
Material to categorize
  1. Key Opinion Leaders and Pediatric Antidepressant Overprescribing.Jon Jureidini & Leemon McHenry - 2009 - Psychotherapy and Psychosomatics 78:197-201.
    The lingering controversy concerning the usefulness and safety of antidepressants for children and adolescents is likely to confuse clinicians. Recent papers perpetuate the claim that antidepressants are shown to be safe and effective in randomised controlled trials. Others claim that antidepressants have been shown to prevent suicides. In this editorial we address the manipulation of outcomes that result from academics’ alliance with industry. We explain how industry and key opinion leaders have distorted the clinician’s perception of the safety and usefulness (...)
    Remove from this list  
     
    Export citation  
     
    Bookmark  
  2. On the Origin of Great Ideas: Science in the Age of Big Pharma.Leemon B. McHenry - 2005 - Hastings Center Report 35 (6):17-19.
    This case study reports an instance of SmithKline Beecham's behind-the-scenes ghostwriting a letter to the editor in a medical journal article in the name of an academic physician. In order to respond to criticism that paroxetine caused severe withdrawal effects, SmithKline Beecham's marketing department hired a PR firm to ghostwrite three separate letters to spin a favorable impression of paroxetine vs fluoxetine and published one in the Journal of Clinical Psychiatry.
    Remove from this list   Direct download (5 more)  
     
    Export citation  
     
    Bookmark  
  3. Industry-Corrupted Psychiatric Trials.Leemon McHenry, Jon Jureidini & Jay Amsterdam - 2017 - Psychiatria Polska 51 (6):993-1008.
    The goal of this paper is to expose the research misconduct of pharmaceutical industry-sponsored clinical trials via three short case studies of corrupted psychiatric trials that were conducted in the United States. We discuss the common elements that enable the misrepresentation of clinical trial results including ghostwriting for medical journals, the role of key opinion leaders as co-conspirators with the pharmaceutical industry and the complicity of top medical journals in failing to uphold standards of science and peer review. We conclude (...)
    Remove from this list  
     
    Export citation  
     
    Bookmark  
  4. The Citalopram CIT-MD-18 Pediatric Depression Trial: A Deconstruction of Medical Ghostwriting, Data Manipulation and Academic Malfeasance.Leemon McHenry, Jon Jureidini & Jay Amsterdam - 2016 - International Journal of Risk and Safety in Medicine 28:33-43.
    This paper is a deconstruction of a ghostwritten report of a randomized, double-blind, placebo-controlled efficacy and safety trial of citalopram in depressed children and adolescents conducted in the United States. Court documents revealed that protocol-specified outcome measures showed no statistically significant difference between citalopram and placebo. However, the published article concluded that citalopram was safe and significantly more efficacious than placebo for children and adolescents, with possible adverse effects on patient safety.
    Remove from this list  
     
    Export citation  
     
    Bookmark   1 citation  
  5. At Law: FDA's Compassion for Desperate Drug Companies.George J. Annas - 1990 - Hastings Center Report 20 (1):35.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  6. ‘Drugs That Make You Feel Bad’? Remorse-Based Mitigation and Neurointerventions.Jonathan Pugh & Hannah Maslen - 2017 - Criminal Law and Philosophy 11 (3):499-522.
    In many jurisdictions, an offender’s remorse is considered to be a relevant factor to take into account in mitigation at sentencing. The growing philosophical interest in the use of neurointerventions in criminal justice raises an important question about such remorse-based mitigation: to what extent should technologically facilitated remorse be honoured such that it is permitted the same penal significance as standard instances of remorse? To motivate this question, we begin by sketching a tripartite account of remorse that distinguishes cognitive, affective (...)
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  7. Raising the Barriers to Access to Medicines in the Developing World – The Relentless Push for Data Exclusivity.Diependaele Lisa, Cockbain Julian & Sterckx Sigrid - 2017 - Developing World Bioethics 17 (1):11-21.
    Since the adoption of the WTO-TRIPS Agreement in 1994, there has been significant controversy over the impact of pharmaceutical patent protection on the access to medicines in the developing world. In addition to the market exclusivity provided by patents, the pharmaceutical industry has also sought to further extend their monopolies by advocating the need for additional ‘regulatory’ protection for new medicines, known as data exclusivity. Data exclusivity limits the use of clinical trial data that need to be submitted to the (...)
    Remove from this list   Direct download (4 more)  
     
    Export citation  
     
    Bookmark  
  8. Pharmacists' and Doctors’ Perception of Pharmaceutical Representative’s Ethical Practices of Drug Promotion in Romania. A Comparative Study.Laszlo-Zoltan Sztankovszky, Camelia Soponaru, Magdalena Iorga & Vasile Astarastoae - 2015 - Postmodern Openings 6 (1):189-199.
    The purpose of the study is to identify perception of doctors and pharmacists on drug promotion practices adopted by pharmaceutical representatives. Material and Methods: A total of 72 pharmacists and 65 doctors responded to a questionnaire about their perceptions on drug promotion practices by pharmaceutical representatives, both in relation to pharmacists and doctors in the relationship. Variables such as age, work environment, seniority, were considered. Of all pharmacists who responded to the questionnaire, a percentage of 47.8% say they have no (...)
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  9. Deadly Medicines and Organised Crime: How Big Pharma has Corrupted Healthcare by Peter Gøtzsche.Justin B. Biddle - 2016 - Kennedy Institute of Ethics Journal 26 (2):40-43.
    From the title, Deadly Medicines and Organised Crime: How Big Pharma has Corrupted Healthcare, Peter Gøtzsche makes the thesis of his book very clear. Not only does the pharmaceutical industry contribute to detrimental health outcomes through biased research, deceptive marketing, and disease mongering, but the industry’s business model meets the criteria of an organized criminal operation. Gøtzsche argues for this in two parts. First, he defines organized crime by drawing upon the United States Organized Crime Control Act of 1970, the (...)
    Remove from this list   Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  10. Body-Self Dualism in Contemporary Ethics and Politics.Patrick Lee & Robert P. George - 2007 - Cambridge University Press.
    Profoundly important ethical and political controversies turn on the question of whether biological life is an essential aspect of a human person, or only an extrinsic instrument. Lee and George argue that human beings are physical, animal organisms - albeit essentially rational and free - and examine the implications of this understanding of human beings for some of the most controversial issues in contemporary ethics and politics. The authors argue that human beings are animal organisms and that their personal identity (...)
    Remove from this list   Direct download  
     
    Export citation  
     
    Bookmark   15 citations  
  11. Pharmaceutical Company Corruption and the Moral Crisis in Medicine.Sharon Batt - 2016 - Hastings Center Report 46 (4):10-13.
    A much-debated series of articles in the New England Journal of Medicine in May 2015 labeled the pharmaceutical industry's critics “pharmascolds.” Having followed the debate for two decades, I count myself among the scolds. The weight of the evidence overwhelmingly supports the claim that pharmaceutical policy no longer serves the public interest; the central questions now are how this happened and what to do about it. I approached three of the most recent books on the industry with these questions in (...)
    Remove from this list   Direct download (4 more)  
     
    Export citation  
     
    Bookmark  
  12. The Disposable Author:How Pharmaceutical Marketing Is Embraced Within Medicine's Scholarly Literature.Alastair Matheson - 2016 - Hastings Center Report 46 (4):31-37.
    The best studies on the relationship between pharmaceutical corporations and medicine have recognized that it is an ambiguous one. Yet most scholarship has pursued a simpler, more saleable narrative in which pharma is a scheming villain and medicine its maidenly victim. In this article, I argue that such crude moral framing blunts understanding of the murky realities of medicine's relationship with pharma and, in consequence, holds back reform. My goal is to put matters right in respect to one critical area (...)
    Remove from this list   Direct download (4 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  13. Roy Church and E. M. Tansey, Burroughs Wellcome & Co.: Knowledge, Trust and Profit, and the Transformation of the British Pharmaceutical Industry, 1880–1940. Lancaster: Crucible, 2007. Pp. Xxvii+564. ISBN 978-1-905-472-07-9. £19.99. [REVIEW]Claire Jones - 2009 - British Journal for the History of Science 42 (2):288.
    Remove from this list   Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  14. Academic Scientists and the Pharmaceutical Industry: Cooperative Research in Twentieth-Century America. John P. Swann.Leon Gortler - 1990 - Isis 81 (1):136-137.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  15. Medical Science and Medical Industry: The Formation of the American Pharmaceutical Industry. Jonathan Liebenau.John P. Swann - 1988 - Isis 79 (3):521-523.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  16. Old Drugs in New BottlesResearches in the History of Pharmaceutical ChemistryGerald Schröder Robert Bohlmann Winfred Schröder Dietrich Arends Erika Hickel Wolfgang Schneider Herbert Wietschoreck Bhulabhai Patel Christian Wehle Mechthild Krüger Horst Matthias Real.Robert P. Multhauf - 1972 - Isis 63 (3):408-412.
    Remove from this list   Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  17. Feeling Is Believing: Evaluative Conditioning and the Ethics of Pharmaceutical Advertising.Paul Biegler & Patrick Vargas - 2016 - Journal of Bioethical Inquiry 13 (2):271-279.
    A central goal in regulating direct-to-consumer advertising of prescription pharmaceuticals is to ensure that explicit drug claims are truthful. Yet imagery can also alter viewer attitudes, and the degree to which this occurs in DTCA is uncertain. Addressing this data gap, we provide evidence that positive feelings produced by images can promote favourable beliefs about pharmaceuticals. We had participants view a fictitious anti-influenza drug paired with unrelated images that elicited either positive, neutral or negative feelings. Participants who viewed positive images (...)
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  18. Ethical Relation Between Physicians and Pharmaceutical Industries in the Perspectives of Bangladesh.Shahinul Alam, Nahiduz Saman, Monsur Hallaj Hallaj, Jahangir Ul Alam & Shoaib Momen Majumder - 2015 - Bangladesh Journal of Bioethics 6 (1):1-5.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  19. Human Rights Responsibilities of Pharmaceutical Companies in Relation to Access to Medicines.Joo-Young Lee & Paul Hunt - 2012 - Journal of Law, Medicine and Ethics 40 (2):220-233.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  20. INTRODUCTION: Institutional Corruption and the Pharmaceutical Policy.Marc A. Rodwin - 2013 - Journal of Law, Medicine and Ethics 41 (3):544-552.
    Remove from this list   Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  21. INTRODUCTION: Pharmaceutical Firms and the Right to Health.Thana Cristina de Campos & Thomas Pogge - 2012 - Journal of Law, Medicine and Ethics 40 (2):183-187.
    Remove from this list   Direct download (4 more)  
     
    Export citation  
     
    Bookmark  
  22. Drug Firms, the Codification of Diagnostic Categories, and Bias in Clinical Guidelines.Lisa Cosgrove & Emily E. Wheeler - 2013 - Journal of Law, Medicine and Ethics 41 (3):644-653.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark   5 citations  
  23. Pharmaceutical Companies and Global Lack of Access to Medicines: Strengthening Accountability Under the Right to Health.Anand Grover, Brian Citro, Mihir Mankad & Fiona Lander - 2012 - Journal of Law, Medicine and Ethics 40 (2):234-250.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  24. Rooting Out Institutional Corruption to Manage Inappropriate Off-Label Drug Use.Marc A. Rodwin - 2013 - Journal of Law, Medicine and Ethics 41 (3):654-664.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark   8 citations  
  25. The Ethics of Pharmaceutical Research Funding: A Social Organization Approach.Garry C. Gray - 2013 - Journal of Law, Medicine and Ethics 41 (3):629-634.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  26. Pharmaceutical Companies Vs. The State: Who is Responsible for Post-Trial Provision of Drugs in Brazil?Daniel Wei L. Wang & Octavio Luiz Motta Ferraz - 2012 - Journal of Law, Medicine and Ethics 40 (2):188-196.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  27. Brightening Up: The Effect of the Physician Payment Sunshine Act on Existing Regulation of Pharmaceutical Marketing.Igor Gorlach & Genevieve Pham-Kanter - 2013 - Journal of Law, Medicine and Ethics 41 (1):315-322.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  28. Five Un-Easy Pieces of Pharmaceutical Policy Reform.Marc A. Rodwin - 2013 - Journal of Law, Medicine and Ethics 41 (3):581-589.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark   7 citations  
  29. Reforming Pharmaceutical Industry-Physician Financial Relationships: Lessons From the United States, France, and Japan.Marc A. Rodwin - 2011 - Journal of Law, Medicine and Ethics 39 (4):662-670.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  30. Pharmaceutical Meaning-Making Beyond Marketing: Racialized Subjects of Generic Thiazide.Anne Pollock - 2008 - Journal of Law, Medicine and Ethics 36 (3):530-536.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  31. An Overview of Prescription Drug Misuse and Abuse: Defining the Problem and Seeking Solutions.Bonnie B. Wilford, James Finch, Dorynne J. Czechowicz & David Warren - 1994 - Journal of Law, Medicine and Ethics 22 (3):197-203.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark   4 citations  
  32. FDA and Drug Safety: New Tufts Study Challenges Critics of the Prescription Drug User Fee Act.Rochelle Lee - 2006 - Journal of Law, Medicine and Ethics 34 (1):131-134.
    Remove from this list   Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  33. Standardizing Psychotropic Drugs and Drug Practices in the Twentieth Century: Paradox of Order and Disorder.Toine Pieters & Stephen Snelders - 2011 - Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences 42 (4):412-414.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  34. Integrating Research and Development: The Emergence of Rational Drug Design in the Pharmaceutical Industry.Matthias Adam - 2005 - Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences 36 (3):513-537.
    Rational drug design is a method for developing new pharmaceuticals that typically involves the elucidation of fundamental physiological mechanisms. It thus combines the quest for a scientific understanding of natural phenomena with the design of useful technology and hence integrates epistemic and practical aims of research and development. Case studies of the rational design of the cardiovascular drugs propranolol, captopril and losartan provide insights into characteristics and conditions of this integration. Rational drug design became possible in the 1950s when theoretical (...)
    Remove from this list   Direct download (4 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  35. The Pharmaceutical Industry in the Biotech Century: Toward a History of Science, Technology and Business?Jean-Paul Gaudillière - 2001 - Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences 32 (1):191-201.
    Remove from this list   Direct download (2 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  36. The Legalization of Drugs.Doug Husak & Peter de Marneffe - 2005 - Cambridge University Press.
    In the United States today, the use or possession of many drugs is a criminal offense. Can these criminal laws be justified? What are the best reasons to punish or not to punish drug users? These are the fundamental issues debated in this book by two prominent philosophers of law. Douglas Husak argues in favor of drug decriminalization, by clarifying the meaning of crucial terms, such as legalize, decriminalize, and drugs; and by identifying the standards by which alternative drug policies (...)
    Remove from this list  
     
    Export citation  
     
    Bookmark   1 citation  
  37. The Legal Status of Unapproved Generic Drugs.Richard R. Abood - 1982 - Journal of Law, Medicine and Ethics 10 (1):24-28.
    Remove from this list   Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  38. Pharmaceutical Industry Financial Support for Medical Education: Benefit, or Undue Influence?Howard Brody - 2009 - Journal of Law, Medicine and Ethics 37 (3):451-460.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  39. Using Patent Data to Assess the Value of Pharmaceutical Innovation.Aaron S. Kesselheim & Jerry Avorn - 2009 - Journal of Law, Medicine and Ethics 37 (2):176-183.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  40. Children's Sense of Self in Relation to Clinical Processes: Portraits of Pharmaceutical Transformation.Elizabeth Carpenter-Song - 2009 - Ethos: Journal of the Society for Psychological Anthropology 37 (3):257-281.
    Remove from this list   Direct download (2 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  41. Curing the Disobedient Patient: Medication Adherence Programs as Pharmaceutical Marketing Tools.Matt Lamkin & Carl Elliott - 2014 - Journal of Law, Medicine and Ethics 42 (4):492-500.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  42. Diagnosing Drug Shortages.Matthew Farr - unknown
    Wealthy countries are increasingly experiencing shortages of a wide range of generic drugs. These shortages are creating substantial harms for patients and problems for health systems. Despite recurring shortages and industry investigations, the nature and character of the drug shortage crisis remain the same: shortage drugs provide slim or negative profit margins, generic drug companies are reluctant to invest in quality improvements, and manufacturers are finding more reason to exit shortage drug markets. This thesis catalogues and explores these and other (...)
    Remove from this list  
     
    Export citation  
     
    Bookmark  
  43. On "New Cardiovascular Drugs: Patterns of Use and Association with Non-Drug Health Expenditures".F. R. Lichtenberg - 2006 - Inquiry: The Journal of Health Care Organization, Provision, and Financing 43 (1):80-82.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  44. The Timing of Introduction of Pharmaceutical Innovations in Seven European Countries.Ragnar Westerling, Marcus Westin, Martin McKee, Rasmus Hoffmann, Iris Plug, Grégoire Rey, Eric Jougla, Katrin Lang, Kersti Pärna, José L. Alfonso & Johan P. Mackenbach - 2014 - Journal of Evaluation in Clinical Practice 20 (4):301-310.
    Remove from this list   Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  45. The Medicalization of Love and Narrow and Broad Conceptions of Human Well-Being.Sven Nyholm - 2015 - Cambridge Quarterly of Healthcare Ethics 24 (3):337-346.
    Would a “medicalization” of love be a “good” or “bad” form of medicalization? In discussing this question, Earp, Sandberg, and Savulescu primarily focus on the potential positive and negative consequences of turning love into a medical issue. But it can also be asked whether there is something intrinsically regrettable about medicalizing love. It is argued here that the medicalization of love can be seen as an “evaluative category mistake”: it treats a core human value as if it were mainly a (...)
    Remove from this list   Direct download (2 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  46. Filling in the Gaps: Priming and the Ethics of Pharmaceutical Advertising.Paul Biegler - 2015 - Kennedy Institute of Ethics Journal 25 (2):193-230.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  47. Drug Familiarization and Therapeutic Misconception Via Direct-to-Consumer Information.Jean-Christophe Bélisle-Pipon & Bryn Williams-Jones - 2015 - Journal of Bioethical Inquiry 12 (2):259-267.
    Promotion of prescription drugs may appear to be severely limited in some jurisdictions due to restrictions on direct-to-consumer advertising. However, in most jurisdictions, strategies exist to raise consumer awareness about prescription drugs, notably through the deployment of direct-to-consumer information campaigns that encourage patients to seek help for particular medical conditions. In Canada, DTCI is presented by industry and regulated by Health Canada as being purely informational activities, but their design and integration in broader promotional campaigns raise very similar ethical concerns (...)
    Remove from this list   Direct download (2 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  48. Views of Health Journalists, Industry Employees and News Consumers About Disclosure and Regulation of Industry-Journalist Relationships: An Empirical Ethical Study.W. Lipworth, I. Kerridge, B. Morrell, R. Forsyth & C. F. C. Jordens - 2015 - Journal of Medical Ethics 41 (3):252-257.
    Remove from this list   Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  49. The Neuropathology Of Drug Addictions And Substance Misuse.Victor R. Preedy (ed.) - forthcoming - Elsevier.
    Remove from this list  
     
    Export citation  
     
    Bookmark  
  50. Curing the Disobedient Patient: Medication Adherence Programs as Pharmaceutical Marketing Tools.Matt Lamkin & Carl Elliott - 2014 - Journal of Law, Medicine and Ethics 42 (4):492-500.
    Pharmaceutical companies have long focused their marketing strategies on getting doctors to write more prescriptions. But they lose billions in potential sales when patients do not take their prescribed drugs. Getting patients to “adhere” to drug therapies that have unpleasant side effects and questionable efficacy requires more than mere ad campaigns urging patients to talk to their doctors. It requires changing patients' beliefs and attitudes about their medications through repeated contact from people patients trust. Since patients do not trust drug (...)
    Remove from this list   Direct download (5 more)  
     
    Export citation  
     
    Bookmark   4 citations  
1 — 50 / 657